Cargando...
Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID‐19 pandemic
Coronavirus disease 2019 (COVID‐19) is responsible for at least 2 546 527 cases and 175 812 deaths as of April 21, 2020. Psoriasis and atopic dermatitis (AD) are common, chronic, inflammatory skin conditions, with immune dysregulation as a shared mechanism; therefore, mainstays of treatment include...
Gardado en:
| Publicado en: | Dermatol Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7283778/ https://ncbi.nlm.nih.gov/pubmed/32458536 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dth.13687 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|